Search Results - "Mendiratta, Prateek"

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma by Retseck, Janet, Nasr, Alexis, Lin, Yan, Lin, Huang, Mendiratta, Prateek, Butterfield, Lisa H, Tarhini, Ahmad A

“…We previously reported early on-treatment significant modulation in circulating regulatory T cell (Treg), myeloid derived suppressor cells (MDSC) and…”
Get full text

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma by Barata, Pedro Coelho, De Liano, Alfonso Gomez, Mendiratta, Prateek, Crolley, Valerie, Szabados, Bernadett, Morrison, Laura, Wood, Laura, Allman, Kimberly, Tyler, Allison, Martin, Allison, Gilligan, Timothy, Grivas, Petros, Ornstein, Moshe, Garcia, Jorge A., Powles, Thomas, Rini, Brian I.

“…BACKGROUND The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive…”
Get full text

The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists by Yoon, Justin G., Mohamed, Inas, Smith, Daniel A., Tirumani, Sree H., Paspulati, Raj M., Mendiratta, Prateek, Ramaiya, Nikhil H.

“…Prostate cancer represents one of the leading causes of cancer-related mortality in the United States and the most common cancer among men. Treatment paradigms…”
Get full text

Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer by Domb, Chaim, Garcia, Jorge A, Barata, Pedro C, Mendiratta, Prateek, Rao, Santosh, Brown, Jason R

“…Antibody-drug conjugates and bicycle toxin conjugates represent a tremendous advance in drug delivery technology and have shown great promise in the treatment…”
Get full text

Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer by MENDIRATTA, Prateek, MOSTAGHEL, Elahe, GUINNEY, Justin, TEWARI, Alok K, PORRELLO, Alessandro, BARRY, William T, NELSON, Peter S, FEBBO, Phillip G

“…Despite treatments which lower circulating androgens, advanced prostate cancers often maintain androgen receptor (AR) signaling. The variable response to…”
Get full text

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire by Tarhini, Ahmad, Lin, Yan, Lin, Huang, Rahman, Zahra, Vallabhaneni, Priyanka, Mendiratta, Prateek, Pingpank, James F, Holtzman, Matthew P, Yusko, Erik C, Rytlewski, Julie A, Rao, Uma N M, Ferris, Robert L, Kirkwood, John M

“…Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We…”
Get full text

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies by Barata, Pedro C., Gopalakrishnan, Dhrmesh, Koshkin, Vadim S., Mendiratta, Prateek, Karafa, Matt, Allman, Kimberly, Martin, Allison, Beach, Jennifer, Profusek, Pam, Tyler, Allison, Wood, Laura, Ornstein, Moshe, Gilligan, Timothy, Rini, Brian I., Garcia, Jorge A., Grivas, Petros

“…Background Little is known about the outcomes, safety, and response to subsequent therapies of patients with metastatic urothelial carcinoma (mUC) treated with…”
Get full text

Androgen Deprivation Fortified by Mendiratta, Prateek, Garcia, Jorge

Get full text

Emerging biomarkers and targeted therapies in urothelial carcinoma by Mendiratta, Prateek, Grivas, Petros

“…The use of immunotherapy has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma (UC); however,…”
Get full text

IMPROVING NURSING ASSESSMENT AND EARLY IDENTIFICATION OF IFOSFAMIDERELATED TOXICITY IN CANCER PATIENTS by Sullivan, Jennifer, Virant, Deborah, Bauer, Erica, Mendiratta, Prateek

“…Ifosfamide is a chemotherapy agent that can cause dose-limiting renal and central nervous system (CNS) toxicities, which at its extreme, can lead to renal…”
Get full text

Patient and clinician perspectives about cannabis use while receiving cancer treatment at a comprehensive cancer center (CCC) by Lee, Richard T., Mendiratta, Prateek, Farrell, Megan, Finklea, Shalena, Trapl, Erika, Rao, Santosh Keshay, Gerson, Stanton L., Cullen, Jennifer

“…e24169 Background: Cannabis is gaining popularity worldwide including in the United States with 37 states legalizing access to cannabis. Limited data exist…”
Get full text

Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis by Al Armashi, Abdul Rahman, Thierheimer, Marisa, Bukavina, Laura, Calaway, Adam C., Vince, Randy, Mendiratta, Prateek, Garcia, Jorge A., Brown, Jason R

“…4583 Background: Patients in rural areas in the US often have worse healthcare outcomes due to socioeconomic deprivation, higher rates of smoking, and limited…”
Get full text

A survey of patients with cancer and oncology health-care professionals about cannabis use during treatment by Lee, Richard T, Kim, Elyssa, Mendiratta, Prateek, Farrell, Megan, Finklea, Shalena, Huang, Lauren, Trapl, Erika, Gerson, Stanton, Cullen, Jennifer

“…This study characterizes patient and health-care professional perspectives regarding medical cannabis use at a National Cancer Institute-Designated Cancer…”
Get full text

Real world genomics in metastatic urothelial carcinoma (mUC) by Wu, Sulin, Kyasaram, Ravi Kumar, Wu, Chen-Han Wilfred, Fu, Pingfu, Margevicius, Seunghee P., Garcia, Jorge A., Barata, Pedro C., Mendiratta, Prateek, Brown, Jason R

“…e16583 Background: Next generation sequencing (NGS) has therapeutic value in mUC. Beyond FGFR3 alteration and tumor mutational burden, genetic testing can…”
Get full text

Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials by Morgans, Alicia K., Roy, Soumyajit, Barata, Pedro C., Brown, Jason R, Jia, Angela, Zaorsky, Nicholas George, Rao, Santosh, Mendiratta, Prateek, Armstrong, Andrew J., Sweeney, Christopher, Attard, Gert, James, Nicholas D., Fizazi, Karim, Sun, Yilun, Spratt, Daniel Eidelberg

“…118 Background: Treatment intensification (TI) for men with advanced prostate cancer consistently demonstrates improvements in overall survival (OS) when…”
Get full text

Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC) by Jang, Albert, Wu, Sulin, Sampath Kumar, Hamsa Latha, Kyasaram, Ravi Kumar, Wu, Chen-Han Wilfred, Bukavina, Laura, Calaway, Adam C., Garcia, Jorge A., Barata, Pedro C., Mendiratta, Prateek, Brown, Jason R

“…685 Background: mUC often carries a poor prognosis, and a subset of patients (pts) progresses within weeks of starting frontline therapy. While…”
Get full text

6 Durable response to immunotherapy-based regimens for IMDC favorable risk patients with metastatic clear cell renal cell carcinoma: a pooled analysis of four published randomized control phase 3 trials by Jang, Albert, Margevicius, Seunghee, Fu, Pingfu, Zhong, Mr Jeffrey, Kumar, Ms Hamsa, Calaway, Adam, Shoag, Jonathan, Bukavina, Laura, Jia, Angela, Mendiratta, Prateek, Rao, Santosh, Sheng, Iris, Brown, Jason, Garcia, Jorge, Barata, Pedro

“…Abstract Background An immune checkpoint inhibitor (ICI) backbone of either ICI doublet (ipilimumab-nivolumab [ipi-nivo]) or tyrosine kinase inhibitor (TKI)…”
Get full text

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer by Barata, Pedro C., Cooney, Matthew, Mendiratta, Prateek, Gupta, Ruby, Dreicer, Robert, Garcia, Jorge A.

“…Summary Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play…”
Get full text

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review by Patell, Kanchi, Kurian, Matthew, Garcia, Jorge A., Mendiratta, Prateek, Barata, Pedro C., Jia, Angela Y., Spratt, Daniel E., Brown, Jason R.

“…Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment…”
Get full text

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer by Alyamani, Mohammad, Emamekhoo, Hamid, Park, Sunho, Taylor, Jennifer, Almassi, Nima, Upadhyay, Sunil, Tyler, Allison, Berk, Michael P, Hu, Bo, Hwang, Tae Hyun, Figg, William Douglas, Peer, Cody J, Chien, Caly, Koshkin, Vadim S, Mendiratta, Prateek, Grivas, Petros, Rini, Brian, Garcia, Jorge, Auchus, Richard J, Sharifi, Nima

“…A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) missense that increases metabolic flux from…”
Get full text